RU2560573C2 - FGF-R-Fc СЛИТЫЙ БЕЛОК И ЕГО ИСПОЛЬЗОВАНИЕ - Google Patents

FGF-R-Fc СЛИТЫЙ БЕЛОК И ЕГО ИСПОЛЬЗОВАНИЕ Download PDF

Info

Publication number
RU2560573C2
RU2560573C2 RU2013140184/10A RU2013140184A RU2560573C2 RU 2560573 C2 RU2560573 C2 RU 2560573C2 RU 2013140184/10 A RU2013140184/10 A RU 2013140184/10A RU 2013140184 A RU2013140184 A RU 2013140184A RU 2560573 C2 RU2560573 C2 RU 2560573C2
Authority
RU
Russia
Prior art keywords
seq
fgfr
fusion protein
amino acid
domain
Prior art date
Application number
RU2013140184/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2013140184A (ru
Inventor
Цзяньминь ФАН
Дун ЛИ
Original Assignee
Яньтай Жунчан Байотекнолоджиз Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Яньтай Жунчан Байотекнолоджиз Ко., Лтд. filed Critical Яньтай Жунчан Байотекнолоджиз Ко., Лтд.
Publication of RU2013140184A publication Critical patent/RU2013140184A/ru
Application granted granted Critical
Publication of RU2560573C2 publication Critical patent/RU2560573C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2013140184/10A 2011-05-20 2012-05-18 FGF-R-Fc СЛИТЫЙ БЕЛОК И ЕГО ИСПОЛЬЗОВАНИЕ RU2560573C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201110132218A CN102219860B (zh) 2011-05-20 2011-05-20 FGFR-Fc融合蛋白及其用途
CN201110132218.9 2011-05-20
PCT/CN2012/075706 WO2012159550A1 (zh) 2011-05-20 2012-05-18 FGFR-Fc融合蛋白及其用途

Publications (2)

Publication Number Publication Date
RU2013140184A RU2013140184A (ru) 2015-07-10
RU2560573C2 true RU2560573C2 (ru) 2015-08-20

Family

ID=44776585

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013140184/10A RU2560573C2 (ru) 2011-05-20 2012-05-18 FGF-R-Fc СЛИТЫЙ БЕЛОК И ЕГО ИСПОЛЬЗОВАНИЕ

Country Status (11)

Country Link
US (2) US9273137B2 (enExample)
EP (2) EP3173102B1 (enExample)
JP (1) JP2014513941A (enExample)
KR (2) KR101660336B1 (enExample)
CN (1) CN102219860B (enExample)
AU (1) AU2012261412B2 (enExample)
BR (1) BR112013022285B1 (enExample)
CA (1) CA2834584C (enExample)
DK (1) DK3173102T3 (enExample)
RU (1) RU2560573C2 (enExample)
WO (1) WO2012159550A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CA2880013C (en) * 2012-07-24 2022-11-29 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US20150344855A1 (en) * 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
WO2014190147A2 (en) * 2013-05-23 2014-11-27 Five Prime Therapeutics, Inc. Methods of treating cancer
DK3102577T3 (en) * 2014-02-07 2018-11-12 Principia Biopharma Inc QUINOLONDERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
CN105983093A (zh) * 2015-02-11 2016-10-05 烟台荣昌生物工程有限公司 血管新生因子融合蛋白在制备用于治疗与血管新生相关的眼部疾病药物中的应用
KR102432192B1 (ko) 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
SG11201908528UA (en) * 2017-03-17 2019-10-30 Vaximm Ag Novel pd-l1 targeting dna vaccine for cancer immunotherapy
BR112021003275A2 (pt) 2018-12-07 2021-06-22 Remegen Co., Ltd. inibidor de angiogênese bifuncional e uso do mesmo
CN116143941B (zh) * 2022-09-08 2024-06-04 浙江省血液中心 一种KIR3DL1-IgG-Fc融合重组蛋白、应用及试剂盒
CN116199744B (zh) * 2023-03-23 2024-06-25 湖南中晟全肽生物科技股份有限公司 一种结合fgfr2受体的多肽及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
WO2007014123A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
RU2341198C2 (ru) * 2006-11-27 2008-12-20 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ оценки ангиогенных факторов при химиотерапии рака молочной железы
WO2011060333A1 (en) * 2009-11-13 2011-05-19 Five Prime Therapeutics, Inc. Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
DE102005007665A1 (de) 2005-02-19 2006-08-31 Degussa Ag Folie auf Basis eines Polyamidblends
AU2007257683A1 (en) 2006-06-12 2007-12-21 Symphogen A/S Pan-cell surface receptor- specific therapeutics
PE20081250A1 (es) * 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
ZA200903134B (en) * 2006-11-28 2010-08-25 Centelion Modified soluble FGF receptor FC fusions with improved biological activity
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
CN102171343B (zh) * 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
WO2007014123A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
RU2341198C2 (ru) * 2006-11-27 2008-12-20 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ оценки ангиогенных факторов при химиотерапии рака молочной железы
WO2011060333A1 (en) * 2009-11-13 2011-05-19 Five Prime Therapeutics, Inc. Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DIKOV M.M. et al., A Functional Fibroblast Growth Factor-1 Immunoglobulin Fusion Protein, The Journ. of Biol.Chem., 1998, v.273, n.25, c.15811-15817. *

Also Published As

Publication number Publication date
EP2711376A4 (en) 2015-06-03
AU2012261412B2 (en) 2016-02-25
BR112013022285A2 (pt) 2016-12-06
US20130195864A1 (en) 2013-08-01
WO2012159550A1 (zh) 2012-11-29
KR101660336B1 (ko) 2016-09-27
US20160176945A1 (en) 2016-06-23
AU2012261412A1 (en) 2013-08-29
RU2013140184A (ru) 2015-07-10
EP3173102A1 (en) 2017-05-31
EP2711376A1 (en) 2014-03-26
CN102219860B (zh) 2012-09-12
EP2711376B1 (en) 2018-07-25
CN102219860A (zh) 2011-10-19
KR20130119978A (ko) 2013-11-01
KR20160011241A (ko) 2016-01-29
US9273137B2 (en) 2016-03-01
BR112013022285B1 (pt) 2020-05-12
CA2834584C (en) 2019-05-14
DK3173102T3 (da) 2020-02-24
CA2834584A1 (en) 2012-11-29
JP2014513941A (ja) 2014-06-19
EP3173102B1 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
JP6328164B2 (ja) 血管新生誘導因子に拮抗する融合蛋白質およびその使用
CA2834584C (en) Fgfr-fc fusion protein and use thereof
JP4680997B2 (ja) 血管新生を阻害するキメラタンパク質およびその利用
JP6519090B2 (ja) 血管内皮成長因子融合タンパク質
JP2023527869A (ja) 加齢関連障害の治療法
US20190048063A1 (en) Methods and compositions for modulating angiogenesis and pericyte composition
US9957313B2 (en) FGFR-FC fusion proteins and the use thereof
JP6138304B2 (ja) ＦＧＦＲ−Ｆｃ融合蛋白質およびその使用
WO2016191765A1 (en) Fgfr-fc fusion proteins and the use thereof
HK1195778A (en) Fgfr-fc fusion protein and use thereof
HK1195778B (en) Fgfr-fc fusion protein and use thereof
HK1195779A (en) Fusion protein for antagonizing angiogenesis inducible factors and uses thereof
HK1195779B (en) Fusion protein for antagonizing angiogenesis inducible factors and uses thereof
WO2025042305A1 (ru) Нуклеотидная последовательность, кодирующпя слитый белок pdgfra-hfc
HK1261618B (en) High-affinity anti-vegf antibody